Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|November 17, 2011
3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanismJenny L Wiley, Dana E Selley, Pinglang Wang, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approachesMostafa H Ahmed, Glen E Kellogg, Dana E Selley, et al.
Synapse (New York, N.Y.)|November 5, 1997
Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sectionsT J Martin, L J Sim, D E Selley, et al.
Molecular Pharmacology|October 1, 1993
BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cellsS R Childers, L M Fleming, D E Selley, et al.
European Journal of Pharmacology|February 26, 2000
Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspironeL J Sim-Selley, L J Vogt, R Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2021
Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptorHongguang Ma, Huiqun Wang, James C Gillespie, et al.
Cannabis and Cannabinoid Research|October 31, 2017
Δ<sup>9</sup>-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal CortexMatthew F Lazenka, Minho Kang, Dipanjana Datta De, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 25, 2007
Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical dataJ Cory Kalvass, Emily R Olson, Michael P Cassidy, et al.
European Journal of Pharmacology|October 28, 2004
Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic ratsDiana L Cichewicz, Melinda L Cox, Sandra P Welch, et al.
Pharmacology, Biochemistry, and Behavior|August 21, 2018
Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male miceDena Kota, Mai Alajaji, Deniz Bagdas, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
The Journal of Pharmacology and Experimental Therapeutics|November 17, 2011
3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanismJenny L Wiley, Dana E Selley, Pinglang Wang, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approachesMostafa H Ahmed, Glen E Kellogg, Dana E Selley, et al.
Synapse (New York, N.Y.)|November 5, 1997
Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sectionsT J Martin, L J Sim, D E Selley, et al.
Molecular Pharmacology|October 1, 1993
BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cellsS R Childers, L M Fleming, D E Selley, et al.
European Journal of Pharmacology|February 26, 2000
Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspironeL J Sim-Selley, L J Vogt, R Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2021
Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptorHongguang Ma, Huiqun Wang, James C Gillespie, et al.
Cannabis and Cannabinoid Research|October 31, 2017
Δ<sup>9</sup>-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal CortexMatthew F Lazenka, Minho Kang, Dipanjana Datta De, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 25, 2007
Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical dataJ Cory Kalvass, Emily R Olson, Michael P Cassidy, et al.
European Journal of Pharmacology|October 28, 2004
Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic ratsDiana L Cichewicz, Melinda L Cox, Sandra P Welch, et al.
Pharmacology, Biochemistry, and Behavior|August 21, 2018
Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male miceDena Kota, Mai Alajaji, Deniz Bagdas, et al.
Pageof 15